You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》中銀國際升信達生物(01801.HK)目標價至82元 維持「買入」評級
阿思達克 06-05 10:14
中銀國際研究報告指,信達生物(01801.HK)於ASCO會議上更新有關IBI363的正面數據。該行將IBI363未來的貢獻納入預測,並將公司2025、2026及2027年的收入預測上調至114億元人民幣(下同)、142億元及179億元,目標價由56元升至82元,維持「買入」評級。 報告指,美國FDA已就IBI363用於晚期非小細胞肺癌(sqNSCLC)和黑色素瘤治療發出快速通道指定,國家藥監局亦授予突破性療法認定,公司計劃下半年開展2個第三階段臨床試驗。另外,一項對比IBI363與現有抗癌藥Keytruda的第二階段關鍵臨床試驗正在進行中,標誌著IBI363邁向全球註冊和商業化的重要一步。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account